— With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices — ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) —  Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update. Corporate Highlights from 1Q 2026 to dateAdvanced initial commercial adoption of FemaSeed Complete, positioning Femasys to expand access to first-line fertility treatment through integrated, in-office care by OB/GYNs, supporting earlier intervention prior to referral to higher-cost specialty care. Launched FemaSeed Complete...

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR EB612, the first oral long-acting PTH peptide replacement tablet for hypoparathyroidism – Expanded 50/50 partnership with OPKO; intention to file IND in late 2026; data submitted to ENDO2026 EB618, the first oral OXM (dual GLP-1/Glucagon) tablet for metabolic and fibrotic conditions – data submitted to ENDO2026 Direct Investment led by BVF Partners L.P. to support EB613 pivotal study acceleration and working capital TEL AVIV, May 08, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today reported financial...

  MILAN, May 08, 2026 (GLOBE NEWSWIRE) — Intesa Sanpaolo delivered net income of €2.8 billion in the first quarter of 2026, the best quarterly result in the Bank’s history (+6% vs. Q1 2025). Q1 operating income reached a record €7.2 billion, driven by balanced growth across net interest income, commissions, insurance activities and trading. Net fees and commissions recorded the best first quarter ever, while insurance income reached record levels, both up 3% year-on-year. Operating costs declined by 0.7%. Net income guidance for 2026 is confirmed at around €10 billion. Together, first-quarter revenue growth — driven by fees and commissions and insurance income — along with lower costs and provisions and a CET1 ratio above 13% underline Intesa Sanpaolo’s low risk profile, solid outlook and sustainable profitability. Wealth Management:...

NAPERVILLE, Ill., May 08, 2026 (GLOBE NEWSWIRE) — Track Group, Inc. (OTCQB: TRCK), a global leader in offender tracking and monitoring services, today announced financial results for its fiscal quarter ended March 31, 2026 (“Q2 FY26”). In Q2 FY26, the Company posted (i) total revenue of $8.9 Million (“M”), an increase of approximately 7% over total revenue of $8.4M for the quarter ended March 31, 2025 (“Q2 FY25”); (ii) Q2 FY26 gross profit of $4.5M representing an increase of approximately 9% over Q2 FY25 gross profit of $4.1M; (iii) Q2 FY26 operating income of $0.41M, representing an increase of approximately 830% over Q2 FY25 operating income of $0.04M; (iv) Q2 FY26 Non-GAAP Adjusted EBITDA of $1.55M, representing an increase of approximately 18% over Q2 FY25 Non-GAAP Adjusted EBITDA of $1.32M and (v) Q2 FY26 net income (loss)...

Company Highlights:GAAP net income of $0.6 million, or $0.00 per diluted common share Distributable earnings1 of $0.07, or $0.18 per diluted common share, excluding $22.9 million of net realized losses from the resolution of certain legacy assets Declares cash dividend on common stock of $0.17 per share Servicing portfolio of ~$36.31 billion, agency loan originations of $707.6 million Structured loan portfolio of ~$12.00 billion, originations of $767.6 million and runoff of $861.0 million Closed a $762.6 million collateralized securitization vehicle with enhanced leverage, generating ~$35 million of additional liquidity Purchased $30.7 million of stock at an average price of $7.46 per share, or 66% of book valueUNIONDALE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (NYSE: ABR), today announced financial results...

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026  PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated first half 2026 CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC BCG-exposed and BCG-unresponsive to be presented at AUA 2026 Well-positioned to deliver on key milestones with approximately $1.1 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029DALLAS, May 08, 2026 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates. “We have successfully completed non-clinical and...

ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended March 31, 2026 was $33,799,000 compared with $38,204,000 net revenue for the quarter ended March 31, 2025. The decrease in net revenue was primarily due to lower contract equipment revenues recognized over time and associated freight revenue, which resulted from the timing of orders and shipments. As a percentage of net revenue, gross profit margins increased 200 basis points to 31.7% in the quarter ended March 31, 2026, compared to 29.7% in the quarter ended March 31, 2025. Product engineering and development expenses decreased $52,000 to $629,000 for the quarter ended March 31, 2026, as compared to $681,000 for the quarter ended March 31, 2025 primarily due to...

– Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination – – Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer – – Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 – – Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 – – ALX strengthens leadership team with the appointment of Jeff Knight as Chief Development and...

FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent HighlightsGenerated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025. Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research. Raised approximately $220 million in gross proceeds from our initial public offering in April 2026.“We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research...

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — AMC Global Media Inc. (“AMC Global Media” or the “Company”) (NASDAQ: AMCX) today reported financial results for the first quarter ended March 31, 2026. Chief Executive Officer Kristin Dolan said: “AMC Global Media delivered another quarter of double-digit streaming revenue growth and robust free cash flow generation. We are tracking to plan across all key metrics and are pleased to reiterate our financial outlook for the year. During this changing time in media, we continue to follow our own differentiated playbook as a studio-driven owner of world-class IP, fully distributed across a wide range of owned and partner platforms.” Operational Highlights:Expanded relationship with DISH and Sling TV through new long-term affiliate agreement. Expanded distribution...